JZHT(HK) Capital Services limited
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector 2025-08-28 07:45
AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through 2025-05-19 08:30
AIM's Serum-Free Iterative Rabies Vaccine Receives Acceptance for Market Registration; Institutions Predict Significant Valuation Recovery Potential for the Company 2025-04-08 08:00
AIM Vaccine reduces losses by nearly 90% in 2024, with the iterative major product series opening up space for explosive growth in performance 2025-03-31 08:00
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates 2025-03-24 08:00
AIM Vaccine reported a significant reduction in losses for 2024, with several major products set to launch that are expected to drive substantial revenue growth 2025-03-17 14:30
AIM Vaccine's Serum-Free Iterative Rabies Vaccine Has Received Production License and Will Submit for Market Registration 2025-03-12 07:53
AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines 2025-03-10 08:00
AIM Vaccine's mRNA RSV Vaccine Approved for U.S. Clinical Trials 2025-02-27 08:00
AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S. 2025-02-25 08:00
AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside 2025-02-24 11:20
AIM Vaccine Leverages AI to Advance mRNA Vaccine Development mRNA Shingles Vaccine Submits Clinical Trial Application 2025-02-12 13:15
Guangdong Land Announced 2023 Annual Results 2024-03-27 23:49
Beauty Farm Issues Positive Profit Alert for 2023 2024-02-02 19:43
1